Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corticotropin analogue - Amphastar Pharmaceuticals/Nanjing Hanxin Pharmaceutical

Next Previous
Drug Profile

Corticotropin analogue - Amphastar Pharmaceuticals/Nanjing Hanxin Pharmaceutical

Alternative Names: AMP-110 - Amphastar Pharmaceuticals

Latest Information Update: 26 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Hanxin Pharmaceutical Technology
  • Developer Amphastar Pharmaceuticals; Nanjing Hanxin Pharmaceutical Technology
  • Class Anti-inflammatories; Antiepileptic drugs; Antipsoriatics; Antirheumatics; Corticosteroids; Eye disorder therapies; Hypothalamic hormones; Peptides; Urologics
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 31 Jan 2026 Nanjing Hanxin Pharmaceutical Technology enters into licensing agreement with Amphastar Pharmaceuticals for development of corticotropin analogue in USA and Canada
  • 31 Jan 2026 Phase-I clinical trials in Autoimmune disorders (unspecified route) before March 2026
  • 31 Jan 2026 Phase-I clinical trials in Inflammation in China (unspecified route) before March 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top